NANOMICRO(SH:688690)2024-11-01 09:52Group 1: Financial Performance - The company's revenue for the first three quarters of 2024 reached 550 million yuan, a year-on-year increase of 21.85% [1] - Excluding the newly consolidated revenue from Fuli Instruments of 103 million yuan, the organic revenue was 447 million yuan, remaining stable compared to the previous year [1] - The overall gross margin for the first three quarters was 71.06%, a decrease of nearly 8 percentage points year-on-year [1] - The net profit attributable to shareholders for the first three quarters was 42 million yuan, with a year-on-year growth of 27.32% [2] Group 2: Cost Management - Total expenses for sales, management, and R&D for the first three quarters amounted to 317 million yuan, a decrease of approximately 1.2% year-on-year [1] - The company implemented strict cost control measures starting from the second half of 2023, effectively managing expense growth [2] - The expense ratios were approximately 18% for operating expenses, 13% for management expenses, and 21% for R&D expenses [3] Group 3: Market and Product Development - The chromatography consumables business maintained a growth rate of over 30%, while the optical and IVD businesses remained stable [1] - The company is focusing on the overseas market, with 80% of overseas revenue coming from end customers, primarily pharmaceutical companies [2] - The company plans to enhance its product competitiveness and optimize marketing strategies to capture opportunities in the biopharmaceutical market [2] Group 4: Strategic Acquisitions and Future Outlook - The company has acquired two instrument companies, aiming to build a chromatography technology platform to compete with international leaders [1] - The company is optimistic about the long-term development prospects of the biopharmaceutical industry despite current market challenges [4] - Future growth is expected from the integration of Fuli Instruments and the optimization of the sales and R&D teams [3]